Markets:

Overview

News

Currencies

International

Treasuries

Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

20.01 -0.17 (-0.84%)

Streaming Delayed Price Updated: 3:28 PM EDT, Jul 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

7 Safe Small-Cap Stocks to Buy Now ↗

May 12, 2022

If you're looking for resilient plays with high upside potential, consider these seven safe small-cap stocks to buy.

Via InvestorPlace

Intra-Cellular Therapies Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating ↗

May 11, 2022

Intra-Cellular Therapies stock cleared a key performance benchmark, with its Relative Strength (RS) Rating, rising to 97.

Via Investor's Business Daily

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2022

May 09, 2022

Reports Net Revenues of $120.4 Million for the Three Months Ended March 31, 2022 RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the...

From Amphastar Pharmaceuticals, Inc.

Via AccessWire

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2022

May 02, 2022

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

From Amphastar Pharmaceuticals, Inc.

Via AccessWire

Krystal Biotech Stock Sees Healthy Relative Strength Rating Upgrade ↗

April 14, 2022

On Thursday, Krystal Biotech stock had its Relative Strength (RS) Rating upgraded from to 93, up 88 a day ago.

Via Investor's Business Daily

Amphastar's Generic Ganirelix Acetate Injection Scores FDA Approval ↗

April 08, 2022

Via Benzinga

Earnings Scheduled For March 10, 2022 ↗

March 10, 2022

Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

April 12, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

10 Stocks That Have Moved Over 20% Since The Indices Plummeted ↗

April 08, 2022

The start of 2022 saw a decline in the stock market. For seasoned investors, this was not unexpected, as corrections in the market are commonplace from January through to March.

Via Benzinga

Why Top-Rated IBD 50 Stock Amphastar Pharmaceuticals Added To Its 75% Run ↗

April 08, 2022

FDA action just sent this red-hot biotech stock to a high, continuing its strong run.

Via Investor's Business Daily

Amphastar Receives FDA Approval for Ganirelix Acetate Injection

April 08, 2022

RANCHO CUCAMONGA, CA / ACCESSWIRE / April 8, 2022 / Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated...

From Amphastar Pharmaceuticals, Inc.

Via AccessWire

Sarepta Therapeutics Stock Shows Market Leadership With Jump To 85 RS Rating ↗

April 07, 2022

On Thursdays, Sarepta Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85 from 80 a day earlier.

Via Investor's Business Daily

Supernus Pharmaceuticals Stock Sees Relative Strength Rating Jump To 92 ↗

April 07, 2022

On Thursday, Supernus Pharmaceuticals stock earned an upgrade to its Relative Strength (RS) Rating, from 87 to 92.

Via Investor's Business Daily

Stocks That Hit 52-Week Highs On Thursday ↗

April 07, 2022

On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high...

Via Benzinga

Amphastar Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

April 06, 2022

RANCHO CUCAMONGA, CA / ACCESSWIRE / April 6, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate...

From Amphastar Pharmaceuticals, Inc.

Via AccessWire

Apellis Pharmaceuticals Stock Shows Rising Relative Strength ↗

April 04, 2022

Apellis Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 87 to 91.

Via Investor's Business Daily

Acadia Pharmaceuticals Stock Shows Market Leadership With Jump To 91 RS Rating ↗

March 25, 2022

Acadia Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 88 to 91.

Via Investor's Business Daily

Biocryst Pharmaceuticals Stock Shows Rising Price Performance With Jump To 92 RS Rating ↗

March 23, 2022

Biotech Biocryst Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 88 to 92 Wednesday.

Via Investor's Business Daily

7 “A”-Rated Stocks to Ground Your Portfolio ↗

March 17, 2022

It's a good time to make sure you have "A"-rated stocks in your portfolio. Many of the ones here have my triple-"A" rating.

Via InvestorPlace

Amphastar Pharmaceuticals: Q4 Earnings Insights ↗

March 10, 2022

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement....

Via Benzinga

Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2021

March 10, 2022

Reports Net Revenues of $120.9 Million for the Three Months Ended December 31, 2021 RANCHO CUCAMONGA, CA / ACCESSWIRE / March 10, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or...

From Amphastar Pharmaceuticals, Inc.

Via AccessWire

Earnings Preview For Amphastar Pharmaceuticals ↗

March 09, 2022

Amphastar Pharmaceuticals (NASDAQ:AMPH) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement....

Via Benzinga

Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 10th, 2022

March 03, 2022

RANCHO CUCAMONGA, CA / ACCESSWIRE / March 3, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2021 ended December 31, 2021,...

From Amphastar Pharmaceuticals, Inc.

Via AccessWire

Biotech Travere Therapeutics Stock Earns Relative Strength Rating Upgrade ↗

February 14, 2022

Travere shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg ↗

March 06, 2022

Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (...

Via Benzinga

7 Safe Stocks to Rely On When the Market Swerves ↗

February 09, 2022

When markets that have flown so high for so long start to tumble, along with an economy that transitioning, safe stocks are essential.

Via InvestorPlace

Pacira Pharmaceuticals Stock Scores A Healthy 79 Relative Strength Rating ↗

February 07, 2022

The Relative Strength (RS) Rating for Pacira Pharmaceuticals moved up into a new percentile Monday, as it got a small lift to 79.

Via Investor's Business Daily

Top Russell 2000 Stocks: Trading Opportunities For Next Week ↗

February 06, 2022

A security pattern traces the distinct movements of security prices that, once recognized, helps traders to make informed trading decisions. Let's look at some Russell 2000 stock opportunities by...

Via Talk Markets

64 Biggest Movers From Yesterday ↗

February 01, 2022

Gainers Calithera Biosciences, Inc. (NASDAQ: CALA) shares surged 55.7% to settle at $0.65 on Monday after Ladenburg Thalmann initiated coverage on the stock with a...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

January 31, 2022

Gainers Calithera Biosciences (NASDAQ:CALA) shares moved upwards by 42.8% to $0.6 during Monday's regular session. As of 12:30 EST, Calithera Biosciences's stock...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.